Heparin Versus Saline Locking of Peripheral Venous Catheters (HESAL)

November 16, 2026 updated by: Consorci Sanitari de l'Alt Penedès i Garraf

Heparin Versus Saline Locking of Peripheral Venous Catheters: a Multicenter Retrospective Cohort Study

The goal of this observational study is to learn whether locking peripheral venous catheters with heparin keeps them open (patent) better than locking them with saline, in adults admitted to hospital who have a peripheral venous catheter for intermittent treatment. The main questions it aims to answer are:

  • Is the percentage of blocked peripheral venous catheters higher in patients whose catheters are locked with saline than in those whose catheters are locked with heparin?
  • Do the rates of other catheter-related complications (phlebitis, catheter-related bloodstream infection, extravasation, and leakage at the insertion site) differ between the two groups?
  • Which clinical and drug-related factors are associated with catheter blockage?

Researchers will compare patients admitted to a hospital that routinely locks catheters with saline with patients admitted to a hospital that routinely locks catheters with heparin.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Maintaining the patency of peripheral venous catheters (PVCs) used intermittently is a relevant and unresolved clinical question. Reference care bundles such as Bacteremia Zero and Phlebitis Zero do not explicitly address whether catheters should be locked with saline or heparin, and the evidence comparing both options, especially taking into account the interval between infusions, is limited.

The two hospitals of the Consorci Sanitari de l'Alt Penedès i Garraf offer a natural experiment: Hospital Residència Sant Camil systematically locks PVCs with sodium heparin 20 IU/mL , while Hospital Comarcal de l'Alt Penedès locks them with sterile 0.9% saline. Allocation to each cohort is determined solely by the hospital of admission. Data for the year before the start of the study will be extracted retrospectively from the electronic medical record, where nurses record the status of the catheter and the reason for removal or replacement on each shift.

The primary analysis will compare, with a superiority approach, the percentage of blocked catheters between cohorts, considering only the first catheter inserted in each patient. Logistic regression will adjust for confounders that are unbalanced between cohorts or clinically relevant (age, sex, type and schedule of intravenous medication, anticoagulation, and coagulation disorders). Sensitivity analyses will include all catheters per patient (mixed models or generalized estimating equations) and will exclude patients at particularly high risk of blockage. Assuming an absolute difference of 3% between cohorts, alpha 5%, power 80%, and 5% losses, 1,725 patients per cohort (3,450 in total) are needed. Data analysts will be blinded to the cohort during the primary analysis.

Study Type

Observational

Enrollment (Estimated)

3450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Barcelona
      • Sant Pere de Ribes, Barcelona, Spain, 08810
        • Hospital Residència Sant Camil
        • Contact:
        • Principal Investigator:
          • Esther Moreno Rubio
      • Vilafranca del Penedès, Barcelona, Spain, 08720
        • Hospital Comarcal de l'Alt Penedès
        • Contact:
        • Principal Investigator:
          • Esther Moreno Rubio

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All adults admitted to Hospital Residència Sant Camil or Hospital Comarcal de l'Alt Penedès (both hospital belonging to CSAPG) during the study period who had at least one peripheral venous catheter inserted for intermittent treatment.

Description

Inclusion Criteria:

  • Admitted to Hospital Residència Sant Camil (CSAPG) or Hospital Comarcal de l'Alt Penedès (CSAPG) during the study period
  • At least one peripheral venous catheter for intermittent treatment, not inserted in a medical emergency
  • Aged 18 years or older

Exclusion Criteria:

  • Known allergy to heparin
  • Treatment with systemic unfractionated sodium heparin
  • Dialysis
  • Venous catheter used only for diagnostic tests
  • Venous catheter used only for transfusion of blood products
  • Participation in another clinical study with drugs or procedures that may affect catheter patency
  • Severe heparin-induced thrombocytopenia in recent months
  • Uncontrolled active bleeding during admission
  • Cerebral aneurysm or dissecting aortic aneurysm, except in association with corrective surgery
  • Confirmed or suspected cerebrovascular hemorrhage
  • Severe uncontrolled hypertension
  • Severe coagulation disorders: platelets below 30,000/µL, prothrombin time ratio above 1.7, or activated partial thromboplastin time ratio above 1.7

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: RETROSPECTIVE

Cohorts and Interventions

Group / Cohort
Cohort A: saline locking
Cohort B: heparin locking

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of blocked peripheral venous catheters
Time Frame: Hospital discharge, up to 12 weeks

Percentage of patients whose first peripheral venous catheter was removed or replaced because of blockage (occlusion).

Hospital discharge, up to 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 6, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CSAPG-98

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

IPD Sharing Time Frame

After publication of main results of the study.

IPD Sharing Access Criteria

IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.